Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 52 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

44%

23 trials in Phase 3/4

Results Transparency

15%

3 of 20 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

37Total
Not Applicable (10)
P 1 (3)
P 2 (1)
P 3 (5)
P 4 (18)

Trial Status

Completed20
Unknown17
Recruiting10
Withdrawn2
Not Yet Recruiting2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT06851468Not ApplicableCompletedPrimary

Keverprazan Combined With Amoxicillin for the Treatment of Helicobacter Pylori

NCT06871579Not ApplicableRecruitingPrimary

Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori

NCT07537634Phase 4Recruiting

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

NCT07232095Phase 4RecruitingPrimary

7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy

NCT04949737Recruiting

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

NCT06529159Not ApplicableRecruiting

H. Pylori Eradication With Argon Plasma During Endoscopy

NCT06943781Recruiting

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

NCT07104318Phase 3Not Yet RecruitingPrimary

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

NCT07253948RecruitingPrimary

Distribution Characteristics of Helicobacter Pylori

NCT07122024Phase 4RecruitingPrimary

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

NCT05790525Phase 4CompletedPrimary

Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy

NCT06785922Not ApplicableEnrolling By Invitation

Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori

NCT06687499Phase 4CompletedPrimary

14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection

NCT06687473Phase 4CompletedPrimary

Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains

NCT05053945RecruitingPrimary

Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study

NCT05649709Phase 4CompletedPrimary

Helicobacter Pylori and Vonoprazan Dual Therapy

NCT01273441Phase 4CompletedPrimary

Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice

NCT04198363Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

NCT04753437Phase 1CompletedPrimary

A Study of Vonoprazan in Adults With Helicobacter Pylori

NCT05371249Phase 4UnknownPrimary

Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy

Scroll to load more

Research Network

Activity Timeline